The Porcine Vaccine Market is expected to register a CAGR of 5% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.
The research report on the Porcine Vaccine Market is segmented by vaccine type into live attenuated vaccines, inactivated vaccines, recombinant vaccines, and DNA vaccines. Applications analyzed include swine influenza, porcine reproductive and respiratory syndrome (PRRS), porcine circovirus, foot-and-mouth disease, and other infectious diseases. End-users include veterinary hospitals, swine farms, research institutes, and pharmaceutical manufacturers. The regional analysis covers key markets such as North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market evaluation is presented in US$ for all segmental analyses.
Purpose of the ReportThe report Porcine Vaccine Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Porcine Vaccine Market Segmentation
Technology- Inactivated Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Conjugate Vaccines
- DNA Vaccines
- Diarrhea
- Swine Influenza
- Arthritis
- Bordatella Rhinitis
- Porcine Reproductive and Respiratory Virus
- Porcine Circovirus Associated Disease
- Veterinary Hospitals
- Hog/Pig Production Farm
Strategic Insights
Porcine Vaccine Market Growth Drivers- Rising Prevalence of Swine Diseases and Outbreaks: The increasing incidence of infectious diseases among swine populations is a major driver of the porcine vaccine market. Diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), Classical Swine Fever (CSF), Porcine Circovirus (PCV), and African Swine Fever (ASF) are causing significant economic losses in the global pig farming industry. According to the Food and Agriculture Organization (FAO), ASF alone has led to the culling of millions of pigs in Asia and Europe, severely impacting pork production and supply chains. The growing threat of zoonotic diseases, which can spread from animals to humans, further emphasizes the need for effective vaccination programs. Governments and livestock associations worldwide are promoting mandatory vaccination campaigns to curb disease outbreaks, creating a strong demand for porcine vaccines. As the pork industry remains a critical component of global food security, the adoption of vaccines is expected to rise steadily.
- Growing Pork Consumption Driving Demand for Healthy Livestock: Pork is one of the most widely consumed meats worldwide, with increasing demand in regions like Asia-Pacific, Europe, and Latin America. According to the US Department of Agriculture (USDA), China alone accounts for over 50% of global pork consumption, followed by the European Union and the United States. To meet this growing demand, commercial pig farms are expanding their operations, necessitating robust disease prevention measures, including vaccination programs. Consumers are becoming more conscious of meat quality and safety, leading to stringent regulations on antibiotic use in livestock. Vaccination serves as a critical preventive strategy to reduce reliance on antibiotics while ensuring healthy swine populations. With the intensification of pig farming and higher biosecurity measures, the demand for porcine vaccines is expected to rise significantly in the coming years.
- Advancements in Vaccine Development and Biotechnology:
Continuous advancements in biotechnology and veterinary medicine are enhancing the efficacy and safety of porcine vaccines. The development of recombinant and subunit vaccines, which provide targeted immunity with minimal side effects, is gaining traction. Researchers are also exploring mRNA-based vaccines for swine diseases, similar to the technology used in COVID-19 vaccines, to improve immune response and production efficiency. Additionally, combination vaccines that protect against multiple swine diseases in a single shot are becoming popular, reducing stress on animals and improving compliance among pig farmers. These innovations are driving the market by offering more effective, long-lasting protection against viral and bacterial infections, ultimately improving swine health and farm productivity.
- Increasing Adoption of Autogenous and Custom-Made Vaccines: There is growing adoption of autogenous and custom-made vaccines as a response to emerging and strain-specific infections, due to the custom-made approach using locally isolated pathogens specific to a farm's needs. Autogenous vaccines are more targeted than commercial vaccines, which may not always match evolving virus strains. The growing requirement for customized veterinary care, especially with the emergence of novel swine disease variants in specific regions, is indeed driving the demand for customized solutions. Autogenous vaccines are being supported by regulatory agencies like the USDA Center for Veterinary Biologics for region-specific outbreaks. Increasing veterinary precision medicine will expand the use of customized porcine vaccines very rapidly.
- The Trend Towards DNA and mRNA-Based Swine Vaccines:
The basis of mRNA vaccine success in human medicine has encouraged research into their application in animal health. These include the DNA and mRNA vaccines, whose advantages include faster production times, higher immunogenicity, and superior adaptability to mutating viruses. mRNA vaccines are being developed for various swine diseases such as PRRS and ASF. Preliminary results from some early studies appear promising. For instance, in 2022, a team of European scientists designed an mRNA vaccine candidate for ASF that elicited potent immune responses in pigs. With the advancement of the technology, mRNA-based porcine vaccines will change the game by providing rapid protection against emerging swine diseases. - Increasing Government Policies and Compulsory Vaccination Programs: Governments across the globe are adopting more stringent vaccination policies to safeguard the swine industry from disease outbreaks. Regulators have made vaccination mandatory for certain diseases in the regions such as Europe and Asia where ASF and PRRS have severely struck pig populations. In a further bid to prevent outbreaks, countries like China, Vietnam, and the Philippines have stepped up efforts to accelerate the development of ASF vaccines as well as hasten their distribution. Moreover, the European Food Safety Authority is promoting vaccination in disease control strategies aimed at maintaining stable pig production, making it more likely for increased vaccination adoption with stronger regulatory and financial incentives for swine farmers, so it is going to further fuel the growth of the market.
- Development of Universal or Multivalent Vaccines: There is a growing need for universal or multivalent vaccines that offer broad protection against multiple porcine diseases with a single administration. Currently, farmers must administer multiple vaccines to protect pigs against various infections, increasing labor costs and stress on the animals. The development of next-generation vaccines that can simultaneously prevent major swine diseases, such as PRRS, PCV, and ASF, would greatly enhance disease management efficiency and improve herd immunity. Research into recombinant DNA technology, mRNA vaccines, and cross-protective immunization strategies is paving the way for more effective and versatile vaccine solutions. Companies that successfully develop and commercialize such vaccines could gain a significant competitive advantage in the market.
- Growth of Autogenous Vaccines for Farm-Specific Disease Control: Autogenous vaccines, which are tailor-made for specific farms based on the pathogens affecting a particular herd, are becoming an attractive alternative to conventional vaccines. These vaccines are especially useful for combating antibiotic-resistant bacterial infections and localized viral strains. With increasing restrictions on antibiotic use in livestock production, customized vaccines provide a targeted and sustainable approach to disease prevention. Veterinary pharmaceutical companies can expand their market presence by offering rapid diagnostic services and developing farm-specific vaccine formulations. Collaborating with veterinary clinics and livestock health specialists to integrate autogenous vaccines into herd management programs can further drive adoption.
- Adoption of Digital Health Solutions for Vaccine Monitoring:
The integration of digital health technologies in livestock management is opening new opportunities for vaccine manufacturers and veterinary service providers. Smart vaccine monitoring systems, including RFID tracking, mobile applications, and cloud-based data analytics, allow farmers to track vaccine administration, monitor herd immunity levels, and ensure compliance with disease control protocols. Digital solutions can help optimize vaccination schedules, reduce wastage, and improve overall herd health outcomes. Companies investing in smart vaccination platforms and precision livestock farming technologies can differentiate themselves in the market by offering data-driven disease management solutions. Partnerships with agritech firms and veterinary software providers can further accelerate the adoption of these innovations in commercial pig farms.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Porcine Vaccine Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Porcine Vaccine Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Porcine Vaccine Market is expected to register a CAGR of 5% from 2025-2031.
The major driving factors supporting the Porcine Vaccine Market growth are- Rising Prevalence of Swine Diseases and Outbreaks and Growing Pork Consumption Driving Demand for Healthy Livestock
Key Future Trends in the Porcine Vaccine Market are- Increasing Adoption of Autogenous and Custom-Made Vaccines and The Trend Towards DNA and mRNA
Key companies in the Porcine Vaccine Market are - Bayer AG, Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Sante Animale, Eli Lilly and Company, Merck and Co., Inc., Sanofi S.A, Vetoquinol, Zoetis, Inc.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Porcine Vaccine Market - By Technology
1.3.2 Porcine Vaccine Market - By Disease Indication
1.3.3 Porcine Vaccine Market - By End User
1.3.4 Porcine Vaccine Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PORCINE VACCINE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PORCINE VACCINE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PORCINE VACCINE MARKET - GLOBAL MARKET ANALYSIS
6.1. PORCINE VACCINE - GLOBAL MARKET OVERVIEW
6.2. PORCINE VACCINE - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. PORCINE VACCINE MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
7.1. OVERVIEW
7.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
7.3. INACTIVATED VACCINES
7.3.1. Overview
7.3.2. Inactivated Vaccines Market Forecast and Analysis
7.4. LIVE ATTENUATED VACCINES
7.4.1. Overview
7.4.2. Live Attenuated Vaccines Market Forecast and Analysis
7.5. TOXOID VACCINES
7.5.1. Overview
7.5.2. Toxoid Vaccines Market Forecast and Analysis
7.6. RECOMBINANT VACCINES
7.6.1. Overview
7.6.2. Recombinant Vaccines Market Forecast and Analysis
7.7. CONJUGATE VACCINES
7.7.1. Overview
7.7.2. Conjugate Vaccines Market Forecast and Analysis
7.8. DNA VACCINES
7.8.1. Overview
7.8.2. DNA Vaccines Market Forecast and Analysis
8. PORCINE VACCINE MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
8.1. OVERVIEW
8.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
8.3. DIARRHEA
8.3.1. Overview
8.3.2. Diarrhea Market Forecast and Analysis
8.4. SWINE INFLUENZA
8.4.1. Overview
8.4.2. Swine Influenza Market Forecast and Analysis
8.5. ARTHRITIS
8.5.1. Overview
8.5.2. Arthritis Market Forecast and Analysis
8.6. BORDATELLA RHINITIS
8.6.1. Overview
8.6.2. Bordatella Rhinitis Market Forecast and Analysis
8.7. PORCINE REPRODUCTIVE AND RESPIRATORY VIRUS (PRRSV)
8.7.1. Overview
8.7.2. Porcine Reproductive and Respiratory Virus (PRRSV) Market Forecast and Analysis
8.8. PORCINE CIRCOVIRUS ASSOCIATED DISEASE (PCVAD)
8.8.1. Overview
8.8.2. Porcine Circovirus Associated Disease (PCVAD) Market Forecast and Analysis
8.9. OTHERS
8.9.1. Overview
8.9.2. Others Market Forecast and Analysis
9. PORCINE VACCINE MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. VETERINARY HOSPITALS
9.3.1. Overview
9.3.2. Veterinary Hospitals Market Forecast and Analysis
9.4. HOG/PIG PRODUCTION FARM
9.4.1. Overview
9.4.2. Hog/Pig Production Farm Market Forecast and Analysis
10. PORCINE VACCINE MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Porcine Vaccine Market Overview
10.1.2 North America Porcine Vaccine Market Forecasts and Analysis
10.1.3 North America Porcine Vaccine Market Forecasts and Analysis - By Technology
10.1.4 North America Porcine Vaccine Market Forecasts and Analysis - By Disease Indication
10.1.5 North America Porcine Vaccine Market Forecasts and Analysis - By End User
10.1.6 North America Porcine Vaccine Market Forecasts and Analysis - By Countries
10.1.6.1 United States Porcine Vaccine Market
10.1.6.1.1 United States Porcine Vaccine Market by Technology
10.1.6.1.2 United States Porcine Vaccine Market by Disease Indication
10.1.6.1.3 United States Porcine Vaccine Market by End User
10.1.6.2 Canada Porcine Vaccine Market
10.1.6.2.1 Canada Porcine Vaccine Market by Technology
10.1.6.2.2 Canada Porcine Vaccine Market by Disease Indication
10.1.6.2.3 Canada Porcine Vaccine Market by End User
10.1.6.3 Mexico Porcine Vaccine Market
10.1.6.3.1 Mexico Porcine Vaccine Market by Technology
10.1.6.3.2 Mexico Porcine Vaccine Market by Disease Indication
10.1.6.3.3 Mexico Porcine Vaccine Market by End User
10.2. EUROPE
10.2.1 Europe Porcine Vaccine Market Overview
10.2.2 Europe Porcine Vaccine Market Forecasts and Analysis
10.2.3 Europe Porcine Vaccine Market Forecasts and Analysis - By Technology
10.2.4 Europe Porcine Vaccine Market Forecasts and Analysis - By Disease Indication
10.2.5 Europe Porcine Vaccine Market Forecasts and Analysis - By End User
10.2.6 Europe Porcine Vaccine Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Porcine Vaccine Market
10.2.6.1.1 Germany Porcine Vaccine Market by Technology
10.2.6.1.2 Germany Porcine Vaccine Market by Disease Indication
10.2.6.1.3 Germany Porcine Vaccine Market by End User
10.2.6.2 France Porcine Vaccine Market
10.2.6.2.1 France Porcine Vaccine Market by Technology
10.2.6.2.2 France Porcine Vaccine Market by Disease Indication
10.2.6.2.3 France Porcine Vaccine Market by End User
10.2.6.3 Italy Porcine Vaccine Market
10.2.6.3.1 Italy Porcine Vaccine Market by Technology
10.2.6.3.2 Italy Porcine Vaccine Market by Disease Indication
10.2.6.3.3 Italy Porcine Vaccine Market by End User
10.2.6.4 Spain Porcine Vaccine Market
10.2.6.4.1 Spain Porcine Vaccine Market by Technology
10.2.6.4.2 Spain Porcine Vaccine Market by Disease Indication
10.2.6.4.3 Spain Porcine Vaccine Market by End User
10.2.6.5 United Kingdom Porcine Vaccine Market
10.2.6.5.1 United Kingdom Porcine Vaccine Market by Technology
10.2.6.5.2 United Kingdom Porcine Vaccine Market by Disease Indication
10.2.6.5.3 United Kingdom Porcine Vaccine Market by End User
10.2.6.6 Rest of Europe Porcine Vaccine Market
10.2.6.6.1 Rest of Europe Porcine Vaccine Market by Technology
10.2.6.6.2 Rest of Europe Porcine Vaccine Market by Disease Indication
10.2.6.6.3 Rest of Europe Porcine Vaccine Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Porcine Vaccine Market Overview
10.3.2 Asia-Pacific Porcine Vaccine Market Forecasts and Analysis
10.3.3 Asia-Pacific Porcine Vaccine Market Forecasts and Analysis - By Technology
10.3.4 Asia-Pacific Porcine Vaccine Market Forecasts and Analysis - By Disease Indication
10.3.5 Asia-Pacific Porcine Vaccine Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Porcine Vaccine Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Porcine Vaccine Market
10.3.6.1.1 Australia Porcine Vaccine Market by Technology
10.3.6.1.2 Australia Porcine Vaccine Market by Disease Indication
10.3.6.1.3 Australia Porcine Vaccine Market by End User
10.3.6.2 China Porcine Vaccine Market
10.3.6.2.1 China Porcine Vaccine Market by Technology
10.3.6.2.2 China Porcine Vaccine Market by Disease Indication
10.3.6.2.3 China Porcine Vaccine Market by End User
10.3.6.3 India Porcine Vaccine Market
10.3.6.3.1 India Porcine Vaccine Market by Technology
10.3.6.3.2 India Porcine Vaccine Market by Disease Indication
10.3.6.3.3 India Porcine Vaccine Market by End User
10.3.6.4 Japan Porcine Vaccine Market
10.3.6.4.1 Japan Porcine Vaccine Market by Technology
10.3.6.4.2 Japan Porcine Vaccine Market by Disease Indication
10.3.6.4.3 Japan Porcine Vaccine Market by End User
10.3.6.5 South Korea Porcine Vaccine Market
10.3.6.5.1 South Korea Porcine Vaccine Market by Technology
10.3.6.5.2 South Korea Porcine Vaccine Market by Disease Indication
10.3.6.5.3 South Korea Porcine Vaccine Market by End User
10.3.6.6 Rest of Asia-Pacific Porcine Vaccine Market
10.3.6.6.1 Rest of Asia-Pacific Porcine Vaccine Market by Technology
10.3.6.6.2 Rest of Asia-Pacific Porcine Vaccine Market by Disease Indication
10.3.6.6.3 Rest of Asia-Pacific Porcine Vaccine Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Porcine Vaccine Market Overview
10.4.2 Middle East and Africa Porcine Vaccine Market Forecasts and Analysis
10.4.3 Middle East and Africa Porcine Vaccine Market Forecasts and Analysis - By Technology
10.4.4 Middle East and Africa Porcine Vaccine Market Forecasts and Analysis - By Disease Indication
10.4.5 Middle East and Africa Porcine Vaccine Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Porcine Vaccine Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Porcine Vaccine Market
10.4.6.1.1 South Africa Porcine Vaccine Market by Technology
10.4.6.1.2 South Africa Porcine Vaccine Market by Disease Indication
10.4.6.1.3 South Africa Porcine Vaccine Market by End User
10.4.6.2 Saudi Arabia Porcine Vaccine Market
10.4.6.2.1 Saudi Arabia Porcine Vaccine Market by Technology
10.4.6.2.2 Saudi Arabia Porcine Vaccine Market by Disease Indication
10.4.6.2.3 Saudi Arabia Porcine Vaccine Market by End User
10.4.6.3 U.A.E Porcine Vaccine Market
10.4.6.3.1 U.A.E Porcine Vaccine Market by Technology
10.4.6.3.2 U.A.E Porcine Vaccine Market by Disease Indication
10.4.6.3.3 U.A.E Porcine Vaccine Market by End User
10.4.6.4 Rest of Middle East and Africa Porcine Vaccine Market
10.4.6.4.1 Rest of Middle East and Africa Porcine Vaccine Market by Technology
10.4.6.4.2 Rest of Middle East and Africa Porcine Vaccine Market by Disease Indication
10.4.6.4.3 Rest of Middle East and Africa Porcine Vaccine Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Porcine Vaccine Market Overview
10.5.2 South and Central America Porcine Vaccine Market Forecasts and Analysis
10.5.3 South and Central America Porcine Vaccine Market Forecasts and Analysis - By Technology
10.5.4 South and Central America Porcine Vaccine Market Forecasts and Analysis - By Disease Indication
10.5.5 South and Central America Porcine Vaccine Market Forecasts and Analysis - By End User
10.5.6 South and Central America Porcine Vaccine Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Porcine Vaccine Market
10.5.6.1.1 Brazil Porcine Vaccine Market by Technology
10.5.6.1.2 Brazil Porcine Vaccine Market by Disease Indication
10.5.6.1.3 Brazil Porcine Vaccine Market by End User
10.5.6.2 Argentina Porcine Vaccine Market
10.5.6.2.1 Argentina Porcine Vaccine Market by Technology
10.5.6.2.2 Argentina Porcine Vaccine Market by Disease Indication
10.5.6.2.3 Argentina Porcine Vaccine Market by End User
10.5.6.3 Rest of South and Central America Porcine Vaccine Market
10.5.6.3.1 Rest of South and Central America Porcine Vaccine Market by Technology
10.5.6.3.2 Rest of South and Central America Porcine Vaccine Market by Disease Indication
10.5.6.3.3 Rest of South and Central America Porcine Vaccine Market by End User
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PORCINE VACCINE MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. PORCINE VACCINE MARKET, KEY COMPANY PROFILES
13.1. BAYER AG
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BIMEDA ANIMAL HEALTH
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. BOEHRINGER INGELHEIM GMBH
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. CEVA SANTE ANIMALE
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ELI LILLY AND COMPANY
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. MERCK AND CO., INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. SANOFI S.A
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. VETOQUINOL
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. ZOETIS, INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. HIPRA
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Bayer AG
2. Bimeda Animal Health
3. Boehringer Ingelheim GmbH
4. Ceva Sante Animale
5. Eli Lilly and Company
6. Merck and Co., Inc.
7. Sanofi S.A
8. Vetoquinol
9. Zoetis, Inc.
10. Hipra
11. Elanco
12. Formosa Biomedical Inc.
13. Shoken Pharmaceutical Co., Ltd
14. MSD Animal Health
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For